top of page
Mission
Translating unique human immune responses
into next-generation antibody therapeutics
Story
Memorises Bio® was carved out from Memo Therapeutics AG in 2026, as part of Memo’s acquisition by Ipsen. We carry forward the antibody discovery platform, Dropzylla®, and research activities outside the potravitug program, including the collaboration with CSL on recombinant polyclonal IgG.
More about our science and team is coming soon.
Follow Memorises Bio on LinkedIn for updates
Stay connected
bottom of page